BioCentury
ARTICLE | Clinical News

Ipsen’s $1B bet on Clementia fizzles with FOP trial stop

January 24, 2020 10:29 PM UTC
Updated on Jan 25, 2020 at 2:11 AM UTC

Ipsen has paused the clinical program for palovarotene in FOP, the asset behind its $1 billion acquisition of Clementia. The move puts the CVR that came with the deal at serious risk and could give Regeneron the most advanced program in this rare bone disease.

Ipsen Group (Euronext:IPN) said on Friday that it would pause dosing in patients in Phase III trial of palovarotene to treat patients with fibrodysplasia ossificans progressiva (FOP) as well as ongoing Phase II extension studies in the orphan disease. The decision was based on an interim futility analysis of the trial’s primary endpoint by an independent data monitoring committee (IDMC) which found that the Phase III FOP trial was unlikely to meet the endpoint...